Outcome of board meeting held on Friday, 13th February 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Smruthi Organics reported its Q3 FY26 (quarter ended 31 December 2025) unaudited results. Revenue from operations fell sharply to Rs 2,229.11 lakhs from Rs 3,124.97 lakhs in the same quarter last year, a decline of about 29%. Nine-month revenue was Rs 7,287.84 lakhs versus Rs 8,791.34 lakhs, also down roughly 17%. Despite the revenue drop, nine-month net profit rose to Rs 235.87 lakhs from Rs 133.28 lakhs, a jump of about 77%, aided by lower raw material costs and improved operating efficiency. The company booked a one-time exceptional expense of Rs 45.17 lakhs relating to the new Labour Codes' impact on gratuity. The Statutory Auditors issued an unqualified limited review report with no qualifications or concerns flagged.
Mixed picture for shareholders - top-line is clearly contracting year-on-year which is a concern, but the company is converting operations more efficiently and posting strong profit growth on a nine-month basis. The clean auditor review and absence of any qualifications are positive signals, while the continuing losses in the smaller Formulations division (Rs 32.21 lakhs in 9M FY26) remain a watch point.